Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Conclusion A new drug named tirzepatide has been approved to treat T2DM, and it is expected to be approved for weight loss by activating both GLP-1 and GIP receptors through a unique mechanism
The future of the GLP-1 landscape is still in question, but one thing is clear: demand will not slow down
We reported that liver-specific TGF-/SMAD4 knockout mice develop hemochromatosis through hepcidin loss and increased iron absorption-a model for ferroptosis ( Cell Metab
Emerging preclinical and clinical evidence suggests that GIPR agonism can play a role in reducing the GI AEs of GLP-1R agonism and enable greater therapeutic potential
+ -permeable TRPM4 and TRPM5 channels (Shigeto et al., 2015)
A., Sokolov, A
